Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III clinical trial to evaluate the safety and efficacy of influenza antiviral drug Avigan Tablet(favipiravir) in Covid-19 patients

Trial Profile

A Phase III clinical trial to evaluate the safety and efficacy of influenza antiviral drug Avigan Tablet(favipiravir) in Covid-19 patients

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Apr 2020

At a glance

  • Drugs Favipiravir (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Apr 2020 New trial record
    • 31 Mar 2020 According to an FUJIFILM Toyama Chemical media release, the company has announced today the initiation of a phase III clinical trial to evaluate the safety and efficacy of influenza antiviral drug Avigan Tablet(generic name: favipiravir) in Japan for patients of COVID-19.

Trial Overview

Purpose

This study will evaluate the safety and efficacy of influenza antiviral drug Avigan Tablet(favipiravir) in Covid-19 patients.

Diseases Treated

Indication Qualifiers Patient Segments
COVID 2019 infections treatment -

Subjects

  • Subject Type patients
  • Sex male & female

Trial Details

Organisations

  • Affiliations FUJIFILM Toyama Chemical

Trial Dates

Other Details

  • Design prospective
  • Phase of Trial Phase III
  • Location Japan
  • Focus Therapeutic Use

Interventions

Drugs Route Formulation
FavipiravirPrimary Drug Oral Tablet

Avigan Tablet(favipiravir)

Trial History

Event Date Event Type Comment
02 Apr 2020 New trial record New trial record Updated 02 Apr 2020
31 Mar 2020 Other trial event According to an FUJIFILM Toyama Chemical media release, the company has announced today the initiation of a phase III clinical trial to evaluate the safety and efficacy of influenza antiviral drug Avigan Tablet(generic name: favipiravir) in Japan for patients of COVID-19. Updated 02 Apr 2020

References

  1. FUJIFILM Toyama Chemical. Fujifilm announces the start of a phase III clinical trial of influenza antiviral drug ##8220##Avigan Tablet##8221## on COVID-19 and commits to increasing production. Media-Rel 2020;.

    Media Release
Back to top